Participants 92 155 3
hormone-sensitive advanced or metastatic breast cancer patients
Participants 293 326 3
women with advanced breast cancer
Participants 536 620 5
Ninety-two patients with advanced breast cancer received arzoxifene 20 or 50 mg/day.
